-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
BAY-57-1293
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/348086-71-5.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 348086-71-5 |
| Description | BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex. Potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections with IC50 value of 20 nM for inhibition of the replication of both HSV-1 and HSV-2 in Vero cells, and ED50 value of 0.5 mg/kg for both HSV-1 and HSV-2 in the murine lethal challenge model of disseminated herpes. |
Product Information
| Synonyms | Pritelivir; BAY-57-1293; BAY 57-1293; BAY-57 1293; BAY 57 1293; BAY571293; AIC316; AIC 316; AIC-316 |
| IUPAC Name | N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide |
| Molecular Weight | 402.49 |
| Molecular Formula | C18H18N4O3S2 |
| Canonical SMILES | CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N |
| InChI | InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) |
| InChIKey | IVZKZONQVYTCKC-UHFFFAOYSA-N |
| Boiling Point | 639.4±65.0 °C at 760 mmHg |
| Flash Point | 340.5±34.3 °C |
| Purity | 98% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White powder |
| Application | For research used only |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 617 |
| Exact Mass | 402.08203280 |
| Index Of Refraction | 1.648 |
| In Vivo | Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex. Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis. Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS. |
| PSA | 142.87000 |
| Target | HSV-1: 0.02 μM (IC50) HSV-2: 0.02 μM (IC50) |
| Vapor Pressure | 0.0±1.9 mmHg at 25°C |
| XLogP3-AA | 2.1 |
